Maxim Group Initiates Coverage On Polaryx Therapeutics with Buy Rating, Announces Price Target of $10
Benzinga Newsdesk 8 months ago
NewsPrice TargetInitiationAnalyst Ratings
Maxim Group analyst Jason McCarthy initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $10.
Maxim Group analyst Jason McCarthy initiates coverage on Polaryx Therapeutics (NASDAQ:PLYX) with a Buy rating and announces Price Target of $10.